Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

Jelly Roll's wife Bunnie XO said she got sick and "s--t my brains out" after "microdosing" the weight loss drug tirzepatide, which is often marketed as Mounjaro or Zepbound.

It had started in 2022, just months after the drug was introduced with the brand Mounjaro for diabetes. Tirzepatide was approved as Zepbound in late 2023 as a weight-loss treatment.

Diabetes treatment Mounjaro has been on the health regulator's shortage list since late 2022, while weight-loss drug Zepbound was added in April as demand far outstripped supply. The limited ...

Medical News Today has strict sourcing guidelines and relies on peer-reviewed studies, academic research institutions, and medical journals and associations. We only use quality, credible sources ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage signaling that the company has succeeded in ...

An emerging market for compounded weight loss injections that mimic brand-name drugs such as Ozempic, Wegovy, Mounjaro and ...

Drugs prescribed for weight loss, such as Mounjaro, Ozempic, Wegovy, and Zepbound, have been popular, expensive, and in short supply. To meet the demand, health providers like Hims & Hers had ...

The remaining 68 deaths were linked to individuals treated with either Mounjaro or Zepbound, two diabetes and weight loss drugs that contain the medication tirzepatide. Over this same time period ...

June 24, 2024 Future of Healthcategory Weight-loss drug Zepbound resolves sleep apnea in up to 52% of patients, Lilly says June 21, 2024 Reuters, the news and media division of Thomson Reuters, ...

The popular weight-loss and diabetes medication tirzepatide is no longer in short supply, the Food and Drug Administration said. Eli Lilly's tirzepatide, sold as Zepbound for weight loss and ...